Investigational drug stops toxic proteins tied to neurodegenerative diseases
(University of Pennsylvania School of Medicine) An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic. Results were published in Science Translational Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Drug Combo Slows Functional Decline in ALS Drug Combo Slows Functional Decline in ALS
A fixed-dose combination of sodium phenylbutyrate and taurursodiol slowed the rate of decline in physical function in patients with amyotrophic lateral sclerosis in the pivotal CENTAUR trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 3, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New Drug Combo for ALS Slows Decline in Small Clinical Study
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo. (Source: The Scientist)
Source: The Scientist - September 3, 2020 Category: Science Tags: News & Opinion Source Type: news

Sodium Phenylbutyrate-Taurursodiol Promising for ALS
THURSDAY, Sept. 3, 2020 -- For patients with amyotrophic lateral sclerosis (ALS), function declines more slowly through 24 weeks in those receiving sodium phenylbutyrate-taurursodiol versus placebo, according to a study published in the Sept. 3... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 3, 2020 Category: Pharmaceuticals Source Type: news

New Treatment for Lou Gehrig's Disease Shows Promise
A study of their therapy and clinical trials of other experimental treatments are offering glimmers of hope that paralysis from the disorder can be slowed. (Source: NYT Health)
Source: NYT Health - September 2, 2020 Category: Consumer Health News Authors: Pam Belluck Tags: Amyotrophic Lateral Sclerosis Clinical Trials Research Drugs (Pharmaceuticals) ALS Assn Food and Drug Administration National Institute of Neurological Disorders and Stroke New England Journal of Medicine Koroshetz, Walter J your-feed-he Source Type: news

Experimental Drug Shows Promise Against ALS
WEDNESDAY, Sept. 2, 2020 -- An experimental treatment may help slow the progression of the deadly brain disease amyotrophic lateral sclerosis (ALS), a new study finds. Researchers called the results a promising step in the fight against a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 2, 2020 Category: General Medicine Source Type: news

Scientists identify promising new ALS drug candidates
(University of Liverpool) Scientists have taken a significant step forward in the search to find effective new drug candidates for the treatment of Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2020 Category: International Medicine & Public Health Source Type: news

Clene Nanomedicine Raises Series D Financing of $42.5 Million
SALT LAKE CITY, Aug. 26, 2020 -- (Healthcare Sales & Marketing Network) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it has secured $42.5 million in a Series D financing. The round was led by SymBiosis II, ... Biopharmaceuticals, Neurology, Venture Capital Clene Nanomedicine, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2020 Category: Pharmaceuticals Source Type: news

RNA quality control system goes awry in frontotemporal lobar degeneration
(Osaka University) Researchers from Osaka University have uncovered that the RNA exosome is critical for the degradation of defective repeat RNA derived fromC9orf72 repeat expansions in patients withC9orf72-associated frontotemporal lobar degeneration and amyotrophic lateral sclerosis. The repeat RNA and resultant toxic proteins impaired RNA exosome function, which led to further accumulation of the defective RNA and protein. The findings outline a cycle that may accelerate neurodegeneration. Therapies disrupting the cycle may help treat the disorder. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 24, 2020 Category: Biology Source Type: news

Organoids and sequencing team up for ALS research
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) MDC researchers received a $150,000 pilot project grant from the Chan Zuckerberg Initiative's Neurodegeneration Challenge Network to investigate a defining feature of amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 20, 2020 Category: Biology Source Type: news

Blood Test Identifies People With ALS Blood Test Identifies People With ALS
A panel of eight micro RNA can identify patients with amyotrophic lateral sclerosis/motor neuron disease, researchers report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 28, 2020 Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news

Decoding the Relationship Between Ageing and ALS Decoding the Relationship Between Ageing and ALS
This study aimed to elucidate the pathogenic mechanisms underlying amyotrophic lateral sclerosis. Might cell type-specific ageing be a key contributor to its development?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 24, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

New Hope for ALS New Hope for ALS
Two studies using different approaches to suppress a gene linked to amyotrophic lateral sclerosis (ALS) may signal a new approach for treating the disorder.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 9, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Innovative ALS research fueled by $25 million from NIH
New initiative encourages research to transform treatment and prevention of amyotrophic lateral sclerosis, a devastating disease. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

Clearer understanding of disordered protein could aid ALS, Alzheimer's treatment search
(Lehigh University) A team led by Lehigh University biophysicist Jeetain Mittal and Brown University structural biologist Nicolas Fawzi has been awarded a $3.3 million NIH grant to study the atomistic structure and mechanisms of TAR DNA-binding protein 43 (TDP-43). Neuronal deposits of this protein are found in people living with Alzheimer's and related dementias, as well as people diagnosed with amyotrophic lateral sclerosis (ALS). The research will also investigate interactions with several promising therapeutic targets. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2020 Category: International Medicine & Public Health Source Type: news

Verge Genomics to advance its inhibitors of PIKfyve for the treatment...
Verge Genomics announced this week at BIO International its lead program for amyotrophic lateral sclerosis (ALS) is the endosomal lipid kinase, PIKfyve, with plans to enter clinical trials next year....(PRWeb June 11, 2020)Read the full story at https://www.prweb.com/releases/verge_genomics_to_advance_its_inhibitors_of_pikfyve_for_the_treatment_of_als_and_covid_19/prweb17178507.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 11, 2020 Category: Pharmaceuticals Source Type: news

Researchers identify new genetic defect linked to ALS
(University of Maryland School of Medicine) Researchers at the University of Maryland School of Medicine (UMSOM) have identified how certain gene mutations cause amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The pathway identified by the researchers may also be responsible for a certain form of dementia related to ALS. The finding could offer potential new approaches for treating this devastating condition. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2020 Category: International Medicine & Public Health Source Type: news

Researchers conduct metabolite analysis of ALS patient blood plasma
(North Carolina State University) High-throughput analysis of blood plasma could aid in identification of diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis (ALS). The work sheds further light on a pathway involved in disease progression and appears to rule out an environmental neurotoxin as playing a role in ALS. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 29, 2020 Category: Biology Source Type: news

Genetic doppelgaengers: Emory research provides insight into two neurological puzzles
(Emory Health Sciences) Insight into the pathological mechanisms behind two devastating neurodegenerative diseases: the most common inherited form of amyotrophic lateral sclerosis/ frontotemporal dementia (ALS/FTD) and spinocerebellar ataxia type 36 (SCA36). Expanded repeats lead to peptide gobbledygook in both, but with critical differences. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news

Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
VANCOUVER, British Columbia, April 30, 2020 -- (Healthcare Sales & Marketing Network) -- Alpha Cognition Inc. (ACI) today announced that in a pre-Investigational New Drug (Pre-IND) meeting, the U.S. Food and Drug Administration (USFDA) agreed upon a clini... Biopharmaceuticals, Neurology, FDA Alpha Cognition, Alzheimer's Disease, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news

Researchers delay onset of amyotrophic lateral sclerosis (ALS) in laboratory models
(University of Toronto) Scientists have delayed the onset of amyotrophic lateral sclerosis (ALS) in laboratory models, leaving them cautiously optimistic that the result, combined with other clinical advances, points to a potential treatment for ALS in humans. The researchers targeted neurons in the brain's motor cortex with an engineered protein that prevented their degeneration and delayed the onset of symptoms such as hardening of the neuron's myelin sheath, weight loss and a deterioration in motor skills. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 20, 2020 Category: International Medicine & Public Health Source Type: news

Caring for Relatives With ALS Almost a Full-Time Job for Youth: Study
FRIDAY, March 27, 2020 -- Kids and teens spend as much as five hours a day helping care for relatives with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a new study finds. Although the young people often help with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2020 Category: General Medicine Source Type: news

Scientists identify gene that first slows, then accelerates, progression of ALS in mice
(The Zuckerman Institute at Columbia University) Columbia scientists have provided new insights into how mutations in a gene called TBK1 cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that robs patients of movement, speech and ultimately, their lives. The researchers found that ALS-associated mutations in TBK1 can have both positive and negative effects on the progression of disease in mice genetically modified to have ALS-like symptoms. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 27, 2020 Category: Biology Source Type: news

Comparison of driving capacity among patients with amyotrophic lateral sclerosis and healthy controls using the lane change task - Hayes HA, Hu N, Wang X, Gibson S, Mathy P, Berggren K, Bromberg M.
OBJECTIVE: Compare driving capacity of individuals with Amyotrophic Lateral Sclerosis (ALS) and healthy controls (HC) using a driving simulation program. METHODS: A prospective study was performed on individuals with ALS who reported they were stil... (Source: SafetyLit)
Source: SafetyLit - March 11, 2020 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

New CRISPR base-editing technology slows ALS progression in mice
(University of Illinois at Urbana-Champaign, News Bureau) With a new CRISPR gene-editing methodology, scientists from the University of Illinois at Urbana-Champaign inactivated one of the genes responsible for an inherited form of amyotrophic lateral sclerosis -- a debilitating and fatal neurological disease for which there is no cure. The novel treatment slowed disease progression, improved muscle function and extended lifespan in mice with an aggressive form of ALS. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 26, 2020 Category: International Medicine & Public Health Source Type: news

New Disability Scale Better Assesses ALS Outcomes New Disability Scale Better Assesses ALS Outcomes
A new amyotrophic lateral sclerosis (ALS) disability scale (ROADS) that uses the mathematically rigorous Rasch methodology outperforms the revised ALS Functional Rating Scale (ALSFRS-R) in measuring ALS patient-reported outcomes, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Amylyx drug helps slow ALS progression in mid-stage study
Privately held drug developer Amylyx Pharmaceuticals Inc said on Tuesday its experimental therapy to treat amyotrophic lateral sclerosis (ALS) helped slow the progression of the fatal neurological disorder in a mid-stage study. (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Top 10 Health Questions America Asked Dr. Google In 2019
(CNN) — Google users in the United States had a lot of questions about blood pressure, the keto diet and hiccups in 2019. Those topics were among the 10 most-searched health-related questions on the search engine this year, according to new data from Google. The list was based on search terms collected between January and early December. Last year, the top health-related questions Googled by people in the US included what is amyotrophic lateral sclerosis, or ALS, what is endometriosis and how long does weed stay in your urine. In 2017, what is lupus, how long does the flu last and what causes hiccups were some of the...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 12, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Google Source Type: news

Emerging role of adenosine in brain disorders and amyotrophic lateral sclerosis
(Mary Ann Liebert, Inc./Genetic Engineering News) The role of adenosine in neurodegeneration and neuroregeneration has led to growing attention on adenosine receptors as potential drug targets in a range of brain disorders, including neuroregenerative therapy and treatment for amyotrophyic lateral sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 6, 2019 Category: International Medicine & Public Health Source Type: news

FDA Clears Oral Film Formulation of ALS Drug Riluzole (Exservan) FDA Clears Oral Film Formulation of ALS Drug Riluzole (Exservan)
An oral film formulation of riluzole may help overcome challenges of disease-related dysphagia in patients with amyotrophic lateral sclerosis.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 26, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Exservan (riluzole) Oral Film for the Treatment of Amyotrophic Lateral Sclerosis
WARREN, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 25, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves Aquestive's ALS treatment
The U.S. Food and Drug Administration on Friday approved http://bit.ly/2pIFzi5 Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS). (Source: Reuters: Health)
Source: Reuters: Health - November 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Role of zinc and copper ions in the pathogenetic mechanisms of traumatic brain injury and Alzheimer's disease - Isaev NK, Stelmashook EV, Genrikhs EE.
The disruption of homeostasis of zinc (Zn2+) and copper (Cu2+) ions in the central nervous system is involved in the pathogenesis of many neurodegenerative diseases, such as amyotrophic lateral sclerosis, Wilson's, Creutzfeldt-Jakob, Parkinson's, and Alzhe... (Source: SafetyLit)
Source: SafetyLit - November 22, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Molecular mechanisms linking ALS/FTD and psychiatric disorders, the potential effects of lithium - Limanaqi F, Biagioni F, Ryskalin L, Busceti CL, Fornai F.
Altered proteostasis, endoplasmic reticulum (ER) stress, abnormal unfolded protein response (UPR), mitochondrial dysfunction and autophagy impairment are interconnected events, which contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS)/fro... (Source: SafetyLit)
Source: SafetyLit - November 9, 2019 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Pelosi ’s radical plan would leave ALS patients behind
Last month, House Speaker Nancy Pelosi unveiled aradical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and leave U.S. patients behind. For example,researchers are focused every day on finding new treatments and cures for amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig ’s Disease), but Pelosi’s plan could threaten future treatments for ALS by imposing government-set prices on critical medicines, creating increased uncertainty and eroding incentives for investment into risky research and development (R&D). (Source: The Catalyst)
Source: The Catalyst - October 15, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development ALS Source Type: news

ICYMI: Fighting for a cure to ALS
Yesterday at The Atlantic Festival, I had the chance to speak with Amy, a biopharmaceutical researcher focused on amyotrophic lateral sclerosis (ALS). As a young girl, Amy ’s father inspired her to become a scientist. Years later, his ALS diagnosis made her life’s work personal. (Source: The Catalyst)
Source: The Catalyst - September 25, 2019 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Research and Development ALS Rare Diseases GoBoldly Source Type: news

Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry
Clinical / Medical (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 25, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey and AMG Center For Amyotrophic Lateral Sclerosis (ALS)
NEW HAVEN, Conn., Sept. 18, 2019 -- (Healthcare Sales & Marketing Network) -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, verdiperstat, Amyotrophic Lateral Sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 18, 2019 Category: Pharmaceuticals Source Type: news

Is This a Fasciculation?
Discussion Benign fasciculations are very common and occur in up to 70% of the general population. They occur at different points in people’s lives. They can be brought out by stress, poor sleep hygiene and caffeine. Caffeine has numerous uses especially for regulating sleep and attention. However too much can cause restlessness, jitteriness and sleep deprivation too. The recommended amount of caffeine for a teenager is
Source: PediatricEducation.org - September 16, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

US WorldMeds lands new FDA approval
Louisville-based pharmaceutical company US WorldMeds LLC received Food and Drug Administration approval for a new use of its drug Myobloc. Myobloc can now be used to treat sialorrhea, commonly known as drooling. It's a common and unfortunate symptom that follows many neurological disorders such as Parkinson's Disease, amyotrophic lateral sclerosis (ALS), cerebral palsy and stroke to name a few. "We are committed to helping patients who struggle with confidence due to their sialorrhea," US WorldMeds… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 28, 2019 Category: Pharmaceuticals Authors: Chris Larson Source Type: news

US WorldMeds lands new FDA approval
Louisville-based pharmaceutical company US WorldMeds LLC received Food and Drug Administration approval for a new use of its drug Myobloc. Myobloc can now be used to treat sialorrhea, commonly known as drooling. It's a common and unfortunate symptom that follows many neurological disorders such as Parkinson's Disease, amyotrophic lateral sclerosis (ALS), cerebral palsy and stroke to name a few. "We are committed to helping patients who struggle with confidence due to their sialorrhea," US WorldMeds… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 28, 2019 Category: Biotechnology Authors: Chris Larson Source Type: news

Socialized medicine in Canada: No money to keep you alive, but plenty of government funds to help you commit suicide
(Natural News) The Canadian medical system has a smart way of saving money: helping people commit suicide when their care becomes too costly. This sickening truth about the country’s socialized medicine was recently illustrated by the case of a 41-year-old British Columbia man, Sean Tagert, who had been living with amyotrophic lateral sclerosis, or ALS.... (Source: NaturalNews.com)
Source: NaturalNews.com - August 22, 2019 Category: Consumer Health News Source Type: news

Eye-controlled, power wheelchair performs well for ALS patients - Elliott MA, Malvar H, Maassel LL, Campbell J, Kulkarni H, Spiridonova I, Sophy N, Beavers J, Paradiso A, Needham C, Rifley J, Duffield M, Crawford J, Wood B, Cox EJ, Scanlan JM.
INTRODUCTION: Our pilot study tested the feasibility and performance of an eye-controlled power wheelchair for amyotrophic lateral sclerosis (ALS) patients. METHODS: In this prospective pilot study, participants drove the wheelchair three times aro... (Source: SafetyLit)
Source: SafetyLit - August 12, 2019 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

Motor neurone disease researchers find link to microbes in gut
Study could eventually lead to new treatments for neurodegenerative conditionScientists have found tantalising clues that the devastating condition motor neurone disease may be linked to changes in microbes that live in the gut.Studies in mice revealed that animals bred to develop amyotrophic lateral sclerosis (ALS), a form of the disease that affectedthe cosmologist Stephen Hawking, improved and lived longer when they were given an organism calledAkkermansia muciniphila.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 22, 2019 Category: Science Authors: Ian Sample Science editor Tags: Motor neurone disease Medical research Science Society Microbiology Source Type: news

Molecular 'clutch' puts infection-fighting cells into gear
(National Centre for Biological Sciences) An international team including University of Warwick scientists identifies proteins that drive activation of our immune response. Adaptor proteins act as a 'clutch' to move clusters of proteins within cellsCould open opportunities to design immune cells to combat specific problems. Protein condensates are involved; have been found to play roles in many biological processes and diseases, including Huntington's disease, amyotrophic lateral sclerosis, and types of cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 22, 2019 Category: Biology Source Type: news

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod
Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading. (Source: Reuters: Health)
Source: Reuters: Health - July 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Taking out the protein garbage becomes more difficult as neurons age
(University of Pennsylvania School of Medicine) As cells age, their ability to shed harmful refuse declines. New research suggests that the deterioration of autophagy in aged neurons could be a risk factor for a suite of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), Alzheimer's, and Parkinson's. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2019 Category: International Medicine & Public Health Source Type: news

Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors
GERMANTOWN, Md., July 18, 2019 -- (Healthcare Sales & Marketing Network) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, a... Biopharmaceuticals, Regenerative Medicine, Personnel Neuralstem, Amyotrophic Lateral Sclerosis, spinal cord injury, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 18, 2019 Category: Pharmaceuticals Source Type: news

Higher BMI Linked to Lower ALS Risk Higher BMI Linked to Lower ALS Risk
The hypothesis that high body mass index guards against development of amyotrophic lateral sclerosis is reinforced by new research.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 3, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

An efficient gait dynamics classification method for neurodegenerative diseases using brain signals - Mole SSS, Sujatha K.
Neurons of the human brain are primarily affected by the Huntington's disease (HD), Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease and so on. Classification of these neurodegenerative diseases (NDD) is clinically important to analyze the destruct... (Source: SafetyLit)
Source: SafetyLit - June 30, 2019 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news